Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding JPH, Batterham RL, Calanna S, et al.
New England Journal of Medicine, 2021 · n = 1961
Key finding
Semaglutide 2.4mg weekly resulted in 14.9% mean body weight reduction, with 86.4% achieving ≥5% and 50.5% achieving ≥15% weight loss.
Summary
Landmark RCT showing 2.4mg weekly semaglutide produced 14.9% mean weight loss vs 2.4% for placebo over 68 weeks in adults with obesity.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on Semaglutide
Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)
New England Journal of Medicine · 2023 · Human RCT
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)
New England Journal of Medicine · 2023 · Human RCT
Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)
Nature Medicine · 2022 · Human RCT
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)
JAMA · 2022 · Human RCT
STEP 3: Semaglutide for Weight Management in Severe Obesity
New England Journal of Medicine · 2022 · Human RCT